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Women are generally protected against progressive loss of
kidney function; however, this advantage seems to diminish
with menopause. Because of conflicting reports on the
association between use of hormone therapy and kidney
function we studied 5845 women (1459 on hormone therapy
and 4386 non-users) who were over 66 years of age and had
at least 2 serum creatinine measurements during the 2 year
study period. After adjustment for covariates, hormone use
(estrogen-only, progestin-only, or both) was associated with
a significant loss of estimated GFR as the primary outcome
along with an increased risk of rapid loss of kidney function
as the secondary outcome compared to non-users. This
increased rate of loss was associated with oral but not
transvaginal estrogen use. An increased cumulative dose
of estrogen was also associated with a greater decline in
estimated GFR. Our study shows an independent association
in a dose-dependent manner of estrogen use and loss of
kidney function in this elderly population.
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The female gender is protective with respect to loss of kidney
function,1–5 although this advantage may diminish and
possibly disappear with the onset of menopause,6 suggesting
a relationship between hormonal status and initiation or
progression of renal impairment.
Hormone therapy (HT), estrogen with or without
progestin, is a common medication used by women to treat
symptoms of menopause and prevent chronic conditions
such as osteoporosis.7 Although treatment of menopausal
symptoms is a common indication for short-term use,8,9 the
effects of HT on long-term health outcomes have become
increasingly important, particularly since the Women’s
Health Initiative10–12 and Heart and Estrogen/Progestin
Replacement Study did not find HT to be beneficial.13 In
addition, it is unclear to what extent these results might be
extrapolated to other HT regimens that differ in terms of
dose, composition, and route of administration.14
Reports on the association between use of HT and kidney
function are conflicting, and there are no studies examining the
loss of kidney function as the primary outcome. A small study
described an improvement in creatinine clearance over a 3.5-
month period after initiation of HT,15 and a larger case–control
study reported a greater creatinine clearance in patients using
HT compared with non-users.16 In contrast, another study
reported no change in estimated glomerular filtration rate
(eGFR) in association with HT use over a 5-year period.17
These studies are limited by the fact that they only included
subjects from select populations15–17 or did not account for the
type of HT (that is, estrogen or progestin), cumulative dose, or
route of delivery.16,17 Moreover, there were very few elderly
subjects included in all three studies. The high prevalence of
reduced kidney function in the elderly,5 coupled with the
uncertainty of the effects of HT on kidney function, prompted
our examination of the relationship between estrogen and/or
progestin use and change in eGFR in a cohort of elderly,
community-dwelling women. In addition, we sought to
determine whether route of administration or cumulative dose
of HT was associated with a change in renal function.
RESULTS
There were 7124 subjects X66 years of age identified who
had at least one outpatient measurement of serum creatinine
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in each of the two defined study periods. As outlined in
Figure 1, a total of 1279 subjects were excluded, as they did
not meet the inclusion criteria, for a final study cohort of
5845 subjects.
Baseline subject characteristics by type of HT use are
shown in Table 1. HT users tended to be younger, less likely
to have diabetes, and have a higher baseline eGFR compared
with non-users. There were no differences in angiotensin-
converting enzyme inhibitor or angiotensin-receptor blocker,
lipid-lowering agent, or diuretic use between the groups,
although HT users were more likely to be prescribed
b-blockers and non-steroidal anti-inflammatory drugs.
Estrogens were more commonly used compared with
progestins, either as a single agent or as combination therapy.
A total of 5845 subjects, 4386 non-users and 1459 HT
users, were followed for a median (interquartile range) of
2 (1.9–2.2) years. After adjustment for age, diabetes, comor-
bidity, and baseline eGFR, mean eGFR declined by 1.57 ml/
min/1.73 m2 for HT non-users over the study period.
Compared with non-users, and after adjustment for the
same covariates, HT use was associated with additional
decline in mean eGFR of 1.24 ml/min/1.73 m2 (95% con-
fidence interval (CI) 0.40–2.08; P¼ 0.004) over the study
period. HT use was also associated with a 19% increased risk
of rapid loss of kidney function (odds ratio 19; 95% CI
1.04–1.36) compared with HT non-users.
When examined by type of hormone and compared with
HT non-users, estrogen-only use was associated with an
additional decline in mean eGFR over the study period
(1.21 ml/min/1.73 m2; 95% CI 0.28–2.14), whereas there was
no association between progestin-only or combination
therapy and decline in eGFR (Table 2). In addition, risk of
rapid loss of kidney function was increased by 17% for the
estrogen-only users (odds ratio 1.17, 95% CI, 1.01–1.35) as
compared with that for HT non-users. There was no
increased risk of rapid loss of renal function associated with
progestin-only or combination HT. Inclusion of angiotensin-
converting enzyme inhibitor/angiotensin-receptor blocker or
Female subjects with ≥1 eGFR measurement
during time periods 1 and 2
N=7124
Subjects including in final cohort
N=5845
1279 subjects excluded:
1151 with mean eGFR > 90 mL/min/1.73 m2
90 with > 12 SCr measurements
36 on dialysis prior to start of study
2 with pre-emptive kidney transplant prior to 1 July 2003
Figure 1 | Formation of study cohort and criteria for exclusion.
Table 1 | Baseline subject characteristics by categorical HT use (n=5845)a
Characteristic No use (n=4386) Estrogen only (n=1083) Progestin only (n=40) Both (n=336) P-valueb
Age (years) 77.5±7.2 75.1±6.1 74.4±5.5 72.8±5.2 o0.0001
eGFR (ml/min/1.73 m2) 62.3±17.1 65.4±15.4 63.0±16.0 67.6±15.4 o0.0001
Diabetes (%) 16.6 10.6 22.5 8.6 o0.0001
Chronic disease score 2458 (1789, 3447) 2621 (1853, 3556) 2471 (1868, 3589) 2217 (1555, 3050) 0.0001
Drug use in prior year (%)
ACE-I/ARB 41.9 40.7 45.0 36.3 0.2
b-Blocker 20.8 24.8 35.0 19.9 0.005
Lipid-lowering 21.1 23.0 35.0 21.7 0.10
Diuretics 41.7 46.8 52.5 36.0 0.0008
NSAIDs 35.8 45.3 35.0 37.8 o0.0001
ACE-I, angiotensin-converting enzyme inhibitor; ANOVA, analysis of variance; ARB, angiotensin-receptor blocker; eGFR, estimated glomerular filtration rate; HT, hormone
therapy; NSAID, non-steroidal anti-inflammatory drug.
aAge and eGFR expressed as mean±s.d.; Chronic Disease Score expressed as median and interquartile range.
bP-value calculated by ANOVA for age and eGFR, w2-test for categorical variables, and Kruskal–Wallis test for Chronic Disease Score.
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non-steroidal anti-inflammatory drug use in the model did
not change this relationship.
Estrogen cumulative dose and chronic kidney disease
progression
Figure 2 outlines the distribution of cumulative estrogen dose
for study subjects who were exposed to at least one form of
estrogen (either alone or in conjunction with a progestin)
and illustrates the linear relationship between cumulative
estrogen dose and predicted change in mean eGFR. When
cumulative dose was considered, there was a significant
dose–response relationship between the cumulative dose of
estrogen and the predicted change in mean eGFR. After
adjusting for age, diabetes, comorbidity, and baseline eGFR,
each increase of 100 defined daily dose of estrogen exposure
(equivalent to 100 oral tablets of conjugated estrogen
0.625 mg) was associated with a decline in eGFR of 0.23 ml/
min/1.73 m2 (95% CI 0.10–0.37; P¼ 0.001) over the study
period.
Route of administration and chronic kidney disease
progression
As compared with HT non-users, oral ingestion of estrogen
(either alone or in conjunction with another route of
administration) was associated with significant additional
decline in eGFR over the study period, even after adjusting
for other covariates (1.86 ml/min/1.73 m2 (95% CI 0.92–2.79;
P¼ 0.001), whereas use of transvaginal estrogen alone was
not associated with loss of kidney function (Table 3).
Inclusion of angiotensin-converting enzyme inhibitor, angio-
tensin-receptor blocker or non-steroidal anti-inflammatory
drug use in the model did not change this relationship.
DISCUSSION
Our study is one of the first to examine the relationship
between HT use and decline in kidney function in a large
community-based elderly population. Compared with HT
non-users, HT use was associated with a small, but
statistically significant, decline in eGFR over the study
period, even after adjustment for age, diabetes, baseline
eGFR, and comorbidity. This effect was observed in estrogen-
only users, and was present for oral but not transvaginal use.
There also was evidence of a dose–response relationship
between cumulative estrogen dose and loss of kidney
function. Putting this into clinical context, compared with
non-users of HT, eGFR was predicted to decrease by
approximately 3 ml/min/1.73 m2 more in a woman ingesting
0.625 mg of conjugated estrogen on a daily basis for 2 years,
the average follow-up of our study.
Few studies have examined the effects of HT on change in
kidney function. A small prospective study of 16 diabetic,
hypertensive women ingesting a cyclic combination of oral
Table 2 | Decline in eGFR over the study period for HT use
compared with no use
HT category n DeGFR (ml/min/1.73 m2) (95% CI)a
None 4386 Reference
Estrogen only 1083 1.21 (0.28, 2.14)
Progestin only 40 3.98 (0.30, 8.26)
Estrogen+progestin 336 0.99 (0.56, 2.54)
CI, confidence interval; eGFR, estimated glomerular filtration rate; HT, hormone
therapy.
aAdjusted for baseline eGFR, age, diabetes, and comorbidity.
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Figure 2 | Distribution of cumulative dose for subjects exposed to estrogen and relationship between estrogen exposure and
predicted decline in mean eGFR. eGFR, estimated glomerular filtration rate.
Table 3 | Decline in eGFR over the study period for estrogen
use compared with no HT use
Route of administration n DeGFR (ml/min/1.73 m2) (95% CI)a
None 4386 Reference
At least oral 1103 1.86 (0.92, 2.79)
Transvaginal only 331 0.68 (2.22, 0.86)
Other 25 0.71 (4.69, 6.11)
CI, confidence interval; eGFR, estimated glomerular filtration rate; HT, hormone
therapy.
aAdjusted for baseline eGFR, age, diabetes, and comorbidity.
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estradiol and norgestrel showed a small improvement in
creatinine clearance after 3.5 monthly cycles,15 and a large
case–control study described better creatinine clearance for
HT users compared with that for non-users.16 In contrast, an
observational study of 179 HT users and 312 non-users
reported no change in eGFR over 5 years.17 However, this
study did not differentiate between users of estrogen,
progestins, or combination therapy, which may explain some
of the discrepancies in the study results. Additionally, the two
larger studies did not control for route of HT administration;
many of the effects of estrogen are mediated by first-pass
effects on the liver, and thus result from oral, but not other,
routes of administration of HT.18,19
Estrogen plays a role in the regulation of and response to
some components of the renin–angiotensin system,20 activa-
tion of which is well accepted to be deleterious to renal
function.21 Certainly, ingestion of exogenous estrogens
contained in oral contraceptive results in increased activity
of the renin–angiotensin system,22–25 and increased risk of
nephropathy has been reported in women with HT or oral
contraceptive use.16,25,26 In contrast, a high-estrogen state,
such as pregnancy, is associated with decreased blood
pressure despite increases in circulating components of the
renin–angiotensin system,27 suggesting that there are inherent
differences between the actions of exogenous and endogen-
ous estrogens. Estrogen therapy is also associated with
increased activity of the vasodilator nitric oxide, although
this effect may be tempered by the action of progesterone or
synthetic progestins.28
We are unaware of any other study examining the effects
of route of HT administration on renal function. Among
routes of HT, oral ingestion predicted more rapid loss of
kidney function compared with transvaginal use. It is well
recognized that percutaneous administration of estrogens, in
contrast to oral administration, circumvents first-pass
gastrointestinal and liver metabolism, resulting in lower
levels of estrogen metabolites, and does not cause induction
of liver enzymes to the same degree as that associated with
oral therapy.18 Compared with oral formulations, transder-
mal estradiol appears to have more favorable effects on many
intermediate cardiovascular disease risk markers.14 Although
clinical significance of the differences in pharmacokinetic and
pharmacodynamic profiles between the oral and transdermal
administration of HT is not fully known; particularly in
chronic kidney disease,29,30 transdermal delivery of estrogen
may be a safer alternative in women with hypertension31 or
the metabolic syndrome.32 Due to the ‘uterine first-pass
effect’, hormones delivered transvaginally concentrate in the
uterus and nearby tissues with low systemic exposure;19 this
may have also played a role in the lack of renal effects
observed in our study with the transvaginal hormone
preparations.
In our study, we were unable to control for timing of HT
initiation (perimenopausal versus postmenopausal), or
exposure to HT in the pre-study period, which may be
important factors.33,34 Most of the women in the Nurses’
Health Study, which suggested an estrogen-mediated protec-
tive effect on the cardiovascular system, started HT in the
perimenopausal period. In contrast, the average age of
subjects in the Women’s Health Initiative trial,10 which failed
to demonstrate any cardioprotective effect with exogenous
estrogen, was 10 years after menopause.35 Continuous, but
not intermittent, estradiol replacement prevented progression
of glomerulosclerosis in ovarectomized rats,36 suggesting that
timing of initiation of HT plays a significant role in kidney
function. Indeed, in the study demonstrating an improve-
ment in albuminuria with HT use, most women began
therapy in the perimenopausal period.17 Nevertheless, one
can interpret from our data that in the elderly postmeno-
pausal state use of HT, or at least oral estrogen, appears to
accelerate the decline of renal function.
This study has limitations. First, we were restricted in our
assessment of clinical data. Although we could not confirm
the postmenopausal state, the median age of menopause was
found to be 51 years,37 and our subjects wereX66 years. We
could not control for clinical factors such as blood pressure,
proteinuria, smoking, obesity, or over-the-counter or herbal
medication use, raising the possibility of residual confound-
ing. However, in observational studies, women who take HT
are generally better educated, have higher incomes and better
access to health care, and are healthier even before starting
therapy;33,38 thus, it is possible that the risk demonstrated
with HT use in our study may actually be an underestimate.
While studies involving humans and animals have suggested
that androgens can increase blood pressure and compromise
renal function,39 exclusion of the 24 subjects on combined
estrogen and testosterone did not change the results. While
there are diverse metabolic and clinical effects of different
types of both estrogens and progestins,26,40 our study was not
powered to analyze the renal consequences by use of the
individual synthetic hormone preparations. While there is
potential for misclassification by categorization of data with
respect to ‘rapid loss of kidney function’, our secondary
outcome, this would not affect the primary outcome of our
study (change in eGFR). Finally, we did not calibrate serum
creatinine measurements with the Cleveland Clinic labora-
tory from which the Modification of Diet in Renal Disease
(MDRD) equation is derived; however, given our primary
interest was the change of kidney function, rather than the
absolute value, this should not have influenced our findings.
Our study has many strengths. It is the first to examine the
impact of cumulative estrogen dose and route of adminis-
tration on renal function. The size of the cohort and its
community-based setting increase the generalizability of our
findings, and the pattern of HT use reported is similar to that
in other studies.41 Previous studies have demonstrated that
the duration of our follow-up is adequate to determine loss
of kidney function,42 and the use of computerized drug
prescription data eliminates the impact of recall bias.
In this elderly community-based population, HT in the
form of oral estrogen use was associated, in a dose-dependent
manner, with increased risk of loss of kidney function,
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suggesting that surveillance of renal function may be prudent
in the postmenopausal woman on HT. Although it remains
unclear as to whether or not the effects of HT use on the
kidney persist after discontinuation of medication, or
whether timing of initiation or duration of use plays a role,
the association between estrogen use, and oral estrogen in
particular, and loss of kidney function in our study merits
attention, although confirmatory studies should be per-
formed prior to proposing changes to clinical practice.
MATERIALS AND METHODS
Study population
The Conjoint Ethics Review Board at the University of Calgary
approved this study. A cohort of elderly female subjects aged X66
years was identified from the Calgary Laboratory Services database
in Calgary, Alberta, Canada. This laboratory provides testing for the
entire Calgary Health Region (catchment population 1.1 million)
using a single regional laboratory and standardized methods that are
recalibrated routinely against reference samples. To be eligible for
inclusion, participants required at least one serum creatinine
measurement in each of two study periods: 1 July 2001 to 31
December 2001; 1 and July 2003 to 31 December 2003. To reduce the
impact of episodes of acute renal failure, laboratory measurements
associated with a hospital admission were not included. Subjects
were also excluded from the cohort if they had more than 12
outpatient serum creatinine measurements in either of the 6-month
observation periods, as they were likely to represent patients with
acutely unstable kidney function.5 Renal transplant recipients or
subjects receiving dialysis prior to study entry were also excluded.
Measurement of kidney function and definition of outcomes
eGFR was used to estimate kidney function using the abbreviated
MDRD equation, which includes variables for age, sex, race, and
serum creatinine,43 and has been validated for use for the
elderly.44.Although data for race were not available for the cohort,
less than 1% of the Alberta population is Black; therefore, the
impact at the population level of eliminating race from the estimate
of GFR was expected to be minimal. Furthermore, given the
study’s focus on change in eGFR, information on race was not
necessary. Because of concerns about the validity of the MDRD
equation for subjects with higher levels of kidney function,45
subjects with baseline eGFR values exceeding 90 ml/min/1.73 m2
were excluded.
Serum creatinine measurements were analyzed in the same
laboratory, thus eliminating the potential for inter-laboratory
measurement variation. However, because of possible intra-labora-
tory variation in measurement resulting from changes in calibration
of serum creatinine assays, measurements between the two time
periods were assessed and calibrated in the following manner. First,
a subset of healthy subjects (defined as subjects with no
prescriptions for medications commonly used to treat cardiovas-
cular disease, hypertension, or diabetes mellitus in the year before
the index GFR) younger than 80 years of age was identified. Median
serum creatinine measurement for these subjects, by 1-year age
increments, for the 2001 and the 2003 time periods was then
calculated. The difference between measurements for the two
periods was calculated, and the average of the differences
determined. To correct for systematic differences in serum creatinine
measurements evident from this analysis, 2 mmol/l (0.02 mg/dl) was
subtracted from the serum creatinine measurements in 2003.
The primary outcome was the change in the mean eGFR in ml/
min/1.73 m2 between 2001 and 2003 (mean eGFR 2003mean eGFR
2001) for each subject. The secondary outcome was rapid loss of
kidney function, defined as a decrease in eGFRX4 ml/min/1.73 m2/
year, which is more than a twofold increase in the rate of decline
expected for this population.5
Measure of exposure
Using the unique provincial health care number for each subject,
laboratory data were linked to the provincial administrative Alberta
Blue Cross database to obtain information on prescription drug use
for the exposure period 1 July 2000 to 31 March , 2003 (representing
the end of the fiscal year for which drug data was available). All
residents of Alberta aged X66 years receive insured health services,
including coverage for prescription drugs. HT exposure (for the
period of 1 year prior to initial eGFR measurement up to 31 March
2003) was defined using two approaches.
The first approach measured the presence or absence of exposure
to HT, using four mutually exclusive categories: (1) non-users: no
use of any HT; (2) estrogen and progestin users combined: at least
one prescription for estrogen and at least one prescription for
progestin; (3) estrogen user only: at least one prescription for
estrogen with no prescriptions for progestin; and (4) progestin user
only: at least one prescription for progestin with no prescriptions for
estrogen.
The second approach measured the cumulative HT dose received
during the exposure period, using the anatomical chemical
therapeutic code and defined daily dose (DDD), to standardize
estrogen and progestin exposure as follows:
drug exposure ¼ drug strengthdrug quantity=DDD46
The final approach categorized hormone exposure by ‘route of
administration’: (1) none (reference); (2) at least oral; (3)
transvaginal only; and (4) other. Transvaginal hormone preparations
were considered a separate category, as this route of administration
not only bypasses the first-pass effect (as opposed to oral
formulations), but also results in low systemic availability of
hormones.19 ‘Other’ category of use included users of transdermal
(n¼ 5) or injectable HT preparations.
Measure of covariates
Subjects were identified as having diabetes if they received at least
one prescription for insulin or an oral hypoglycemic agent in the
year before their index serum creatinine measurement. A measure-
ment of comorbidity status, based on the use of prescription drugs,
was calculated using the Chronic Disease Score.47 The Chronic
Disease Score is a validated weighted index of prescription medi-
cations; the greater the number of classes of medications dispensed,
or the seriousness of the disease treated, the higher the score.
Statistical methods
Baseline characteristics by type of HT user are presented as the
mean±s.d. for normally distributed continuous variables and
proportions for dichotomous variables. Differences in baseline
characteristics across categories of HT use were determined by
w2-test, analysis of variance, and Kruskal–Wallis analysis, where
appropriate. The association between HT use (non-users (reference),
estrogen only, progestin only, and estrogen plus progestin) and loss
of kidney function was assessed using multivariate linear regression,
adjusting for age, baseline eGFR, diabetes, and comorbidity score.
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A similar analysis was performed to determine the association
between the route of HT administration (none, at least oral,
transvaginal only, and other), as well as cumulative HT dose (DDD)
and loss of kidney function. Finally, logistic regression was used to
determine the association between HT use categories and rapid loss
of kidney function, adjusting for covariates as previously described.
In all analyses, non-HT users formed the reference group.
Assumptions for both linear and logistic regression models were
tested and met. All analyses were conducted using SAS (version 9.13;
SAS Institute Inc., Cary, NC, USA) or Stata (version 9.1; Stata Corp.,
College Station, TX, USA) with two-tailed significance levels of 0.05.
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